clinical trial · NCT05093634
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
ObesityGenetic ObesitySetmelanotidePlacebo
brief summary
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-study 035b) * SRC1 (Sub-study 035c) * SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
started
Dec 10, 2021
primary completion
Dec 22, 2025
completion
Dec 31, 2026
last updated
Feb 10, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol